The Future of Idiopathic and Progressive Pulmonary Fibrosis Treatment

Opinion
Video

An expert physician discusses the potential role of novel agents in the management of idiopathic and progressive pulmonary fibrosis.

  • An investigational PDE4 inhibitor has been shown to delay progression of disease at 12 weeks in patients with IPF. Why is this exciting for pulmonologists and for patients with IPF as a whole?
  • How do you see these investigational therapies being implemented into future treatment paradigms for patients with IPF/PPF?
Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Screenshot of an interview with Harmony Garges, MD
George O. Waring, IV, MD, during a video interview
1 KOL is featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.